SPRED2 suppresses the stemness of hepatocellular carcinoma through the p53/miR-506-3p/KLF4 pathwayOA
Objective:We previously reported that endogenous Sprouty-related,EVH1 domain-containing protein 2(SPRED2),an inhibitor of the Ras/Raf/ERK-MAPK pathway,controls hepatocellular carcinoma(HCC)cell stemness by downregulating the expression of pluripotency factors,such as Nanog,c-Myc,and KLF4,in an ERK-dependent fashion.However,the exact mechanisms by which SPRED2 regulates HCC cell stemness have not been established.Methods:Three human HCC cell lines[HepG2(parental and SPRED2-deficient),HLE,and Hep3B]were used.Cells were transfected to downregulate or overexpress proteins.Western blot and RT-qPCR were used to evaluate the level of protein and mRNA expression.Co-immunoprecipitation and ChIP-qPCR were used to examine protein-protein interactions and the activation of gene transcription.Clinical HCC tissues were also used to validate in vitro data.Results:KLF4 was identified as the major pluripotency factor responsible for SPRED2-mediated downregulation of HCC cell stemness and KLF4 expression was regulated by miR-506-3p.SPRED2 formed a protein complex with the tumor suppressor(p53)and upregulated miR-506 gene transcription by binding to the promoter region,resulting in subsequent downregulation of KLF4 mRNA expression.There was a negative correlation between KLF4 expression and miR-506-3p and a positive correlation between miR-506-3p expression and SPRED2 in human HCC samples,highlighting the relevance of the study findings.Conclusions:The current study revealed a novel SPRED2/p53/miR-506-3p/KLF4 axis through which SPRED2 contributes to the suppression of HCC cell stemness and provides a potential new target to prevent HCC progression.
Tong Gao;Sachio Ito;Aye Moh-Moh-Aung;Tianyi Wang;Masayoshi Fujisawa;Toshiaki Ohara;Teizo Yoshimura;Akihiro Matsukawa
Department of Pathology and Experimental Medicine,Graduate School of Medicine,Dentistry and Pharmaceutical Sciences,Okayama University,Okayama 700-8558,JapanDepartment of Pathophysiology and Drug Discovery,Graduate School of Medicine,Dentistry and Pharmaceutical Sciences,Okayama University,Okayama 700-8558,JapanDepartment of Pathology and Experimental Medicine,Graduate School of Medicine,Dentistry and Pharmaceutical Sciences,Okayama University,Okayama 700-8558,JapanDepartment of Pathology and Experimental Medicine,Graduate School of Medicine,Dentistry and Pharmaceutical Sciences,Okayama University,Okayama 700-8558,JapanDepartment of Pathology and Experimental Medicine,Graduate School of Medicine,Dentistry and Pharmaceutical Sciences,Okayama University,Okayama 700-8558,JapanDepartment of Pathology and Experimental Medicine,Graduate School of Medicine,Dentistry and Pharmaceutical Sciences,Okayama University,Okayama 700-8558,JapanDepartment of Pathology and Experimental Medicine,Graduate School of Medicine,Dentistry and Pharmaceutical Sciences,Okayama University,Okayama 700-8558,JapanDepartment of Pathology and Experimental Medicine,Graduate School of Medicine,Dentistry and Pharmaceutical Sciences,Okayama University,Okayama 700-8558,Japan
医药卫生
SPRED2p53KLF4miR-506-3pstemness
《Cancer Biology & Medicine》 2026 (9)
P.1283-1302,I0004-I0009,26
supported in part by Japan Society for the Promotion of Science(Grant Nos.25293095,90264283,and 22K19562).
评论